INVESTIGADORES
OLIVERI Maria Beatriz
artículos
Título:
Intravenous bisphosphonate treatment and pregnancy: its effects
Autor/es:
MASTAGLIA SILVINA ROSANA; WATMAN N; OLIVERI BEATRIZ
Revista:
OSTEOPOROSIS INTERNATIONAL
Editorial:
SPRINGER LONDON LTD
Referencias:
Año: 2009
ISSN:
0937-941X
Resumen:
Introduction: Type 1 Gaucher's disease (GD1) is a lysosomal storage disorder
associated with disabling bone involvement. The choice treatment for Gaucher's
disease is enzyme replacement therapy (ERT). The use of bisphosphonate
treatment for osteopenia and osteoporosis has been suggested.
treatment for osteopenia and osteoporosis has been suggested.
Case: A 22-year-old woman diagnosed with GD1 had received ERT
intermittently, depending on availability of the enzyme since the enzyme was
not always available. Due to severe bone involvement and multiple vertebral
fractures, intravenous administration of 60 mg of pamidronate every 3 months
and safe contraception were indicated. Fifteen days after receiving the fourth
infusion, the patient informed us she was pregnant. A baby girl was born by
cesarean delivery at week 37, showing no evidence of skeletal abnormality or
clinical signs of hypocalcemia. The baby developed normally, presenting no
significant pathology. At present (age 15 months), height, body weight, and
bone mineral density by DXA are within normal range. The mother showed
stable total skeleton and right femoral neck bone mineral density (BMD) values,
no new fractures, and only ~3% decrease in lumbar spine BMD 15 months postdelivery
and after a 1 year breastfeeding period (expected average ~78%).A 22-year-old woman diagnosed with GD1 had received ERT
intermittently, depending on availability of the enzyme since the enzyme was
not always available. Due to severe bone involvement and multiple vertebral
fractures, intravenous administration of 60 mg of pamidronate every 3 months
and safe contraception were indicated. Fifteen days after receiving the fourth
infusion, the patient informed us she was pregnant. A baby girl was born by
cesarean delivery at week 37, showing no evidence of skeletal abnormality or
clinical signs of hypocalcemia. The baby developed normally, presenting no
significant pathology. At present (age 15 months), height, body weight, and
bone mineral density by DXA are within normal range. The mother showed
stable total skeleton and right femoral neck bone mineral density (BMD) values,
no new fractures, and only ~3% decrease in lumbar spine BMD 15 months postdelivery
and after a 1 year breastfeeding period (expected average ~78%).
Conclusion: It could be posited that pamidronate exerted a positive protective
effect on the mother's skeleton with no evidence of adverse effects on
pregnancy or on the baby's health to date.It could be posited that pamidronate exerted a positive protective
effect on the mother's skeleton with no evidence of adverse effects on
pregnancy or on the baby's health to date.Type 1 Gaucher's disease (GD1) is a lysosomal storage disorder
associated with disabling bone involvement. The choice treatment for Gaucher's
disease is enzyme replacement therapy (ERT). The use of bisphosphonate
treatment for osteopenia and osteoporosis has been suggested.
treatment for osteopenia and osteoporosis has been suggested.
Case: A 22-year-old woman diagnosed with GD1 had received ERT
intermittently, depending on availability of the enzyme since the enzyme was
not always available. Due to severe bone involvement and multiple vertebral
fractures, intravenous administration of 60 mg of pamidronate every 3 months
and safe contraception were indicated. Fifteen days after receiving the fourth
infusion, the patient informed us she was pregnant. A baby girl was born by
cesarean delivery at week 37, showing no evidence of skeletal abnormality or
clinical signs of hypocalcemia. The baby developed normally, presenting no
significant pathology. At present (age 15 months), height, body weight, and
bone mineral density by DXA are within normal range. The mother showed
stable total skeleton and right femoral neck bone mineral density (BMD) values,
no new fractures, and only ~3% decrease in lumbar spine BMD 15 months postdelivery
and after a 1 year breastfeeding period (expected average ~78%).A 22-year-old woman diagnosed with GD1 had received ERT
intermittently, depending on availability of the enzyme since the enzyme was
not always available. Due to severe bone involvement and multiple vertebral
fractures, intravenous administration of 60 mg of pamidronate every 3 months
and safe contraception were indicated. Fifteen days after receiving the fourth
infusion, the patient informed us she was pregnant. A baby girl was born by
cesarean delivery at week 37, showing no evidence of skeletal abnormality or
clinical signs of hypocalcemia. The baby developed normally, presenting no
significant pathology. At present (age 15 months), height, body weight, and
bone mineral density by DXA are within normal range. The mother showed
stable total skeleton and right femoral neck bone mineral density (BMD) values,
no new fractures, and only ~3% decrease in lumbar spine BMD 15 months postdelivery
and after a 1 year breastfeeding period (expected average ~78%).
Conclusion: It could be posited that pamidronate exerted a positive protective
effect on the mother's skeleton with no evidence of adverse effects on
pregnancy or on the baby's health to date.It could be posited that pamidronate exerted a positive protective
effect on the mother's skeleton with no evidence of adverse effects on
pregnancy or on the baby's health to date.